

## ***Basingstoke, Southampton and Winchester***

### ***District Prescribing Committee (DPC)***

**Recommendations of the meeting of 22<sup>nd</sup> April 2014**

#### **Supported or limited support, e.g. specialist recommendation**

- **Ulipristal (ellaOne®) for emergency contraception**- this was agreed as an option for broader use locally, in line with recent national guidance. It may be offered to women with high BMI, or in whom an intrauterine device is declined or contra-indicated, up to 120 hours (5 days) after intercourse.
- **Fluticasone furoate plus vilanterol (Relvar Ellipta®) combination inhaler for asthma** - recommended for niche use locally as a once daily option in patients who cannot use other inhaler devices. The DPC wished to remind prescribers about the relative potency of fluticasone furoate compared to fluticasone propionate, and the lack of a low dose 'stepping down' inhaler option in asthma.
- **Fluticasone furoate plus vilanterol (Relvar Ellipta®) for COPD** - recommended as a once daily ICS/LABA option in moderate to severe COPD
- **Aripiprazole depot injection**- This was supported for niche use by specialists only, i.e. classed as a 'red' drug locally. It may be helpful when compliance with oral aripiprazole is problematic and weight gain is a serious concern.

#### **Not supported currently**

- **Indacaterol plus glycopyrronium (Ultibro Breezhaler®) in COPD**- This first LABA/LAMA combination inhaler was not supported for use locally at this stage. The evidence was considered "unremarkable", and further data on prevention of exacerbations are required. A reminder that the use of indacaterol alone was not supported by the DPC previously as there was limited data comparing it with existing LABAs, and an overall lack of data comparing it to other symptomatic treatments.

#### **Information/Reminders/Updates/Safety Messages/NICE**

- **Apomorphine in severe Parkinsons disease** - a reminder that this highly specialist medication will be reserved for prescribing by specialists locally for new patients from henceforth (i.e 'red'). Small numbers of existing patients will be transferred back to specialist care, including future prescribing and supply of apomorphine, in a managed way.
- **Octreotide and Lanreotide shared care in acromegaly**- brief shared care guidelines were updated for GP use in existing and new patients. (N.B prescribing in neuroendocrine tumours is now the responsibility of specialists)

**Summarised on behalf of the District Prescribing Committee.**

**Julia Bowey (Southampton City CCG) 20.05.14**